ALMS
NASDAQ HealthcareAlumis Inc. - Common Stock
Biotechnology
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
๐ Market Data
| Price | $27.23 |
|---|---|
| Volume | 1,254,612 |
| Market Cap | 3.47B |
| Beta | -0.710 |
| RSI (14-Day) | 57.5 |
| 200-Day MA | $18.66 |
| 50-Day MA | $24.00 |
| 52-Week High | $31.35 |
| 52-Week Low | $3.25 |
| Forward P/E | -9.22 |
| Price / Book | 6.11 |
๐ฏ Investment Strategy Scores
ALMS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (54/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ALMS in your text
Paste any article, transcript, or post โ the tool will extract ALMS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.